CALGARY, AB, Dec. 18, 2023 /CNW/ – Simply Solventless Concentrates Ltd. (TSXV: HASH) (formerly “Dash Capital Corp.”) (“SSC” or the “Company“) is pleased to announce that it has successfully completed its previously announced qualifying transaction pursuant to TSX Venture Exchange (“TSXV“) Policy 2.4 – Capital Pool Companies by way of reverse takeover (the “RTO“). The parties to the RTO received conditional approval from the TSXV on October 25, 2023. A filing statement dated October 31, 2023 (the “Filing Statement“) with respect to the RTO can be found on the Company’s SEDAR+ profile at www.sedarplus.ca.

Trading in the common shares of the Company (“Common Shares“) is expected to resume on the TSXV on December 20, 2023.

Pursuant to the RTO:

• the Company implemented a consolidation of its then issued and outstanding 11,000,000 Common Shares on the basis of one new Common Share for every two existing Common Shares;
• the private company Simply Solventless Concentrates Ltd. (“SSC PrivateCo“) amalgamated (the “Amalgamation“) with a wholly owned subsidiary of the Company, 2366191 Alberta Ltd. (“Subco“), to form Massive Hash Factory Ltd., a new wholly-owned subsidiary of the Company;
• all issued and outstanding common shares of SSC Private Co were cancelled and each former holder thereof, other than former holders who validly dissented in respect of the Amalgamation, is entitled to receive such number of common shares (“Common Shares“) of the Company for each one common share of SSC PrivateCo previously held; and
• the Company changed its name to “Simply Solventless Concentrates Ltd.”

Following completion of the RTO, the directors and officers of SSC are:

• Jeff Swainson, President, CEO and director
• Jeff Hall, Chief Financial Officer
• William Macdonald, director
• Colin Davison, director
• Steve Bjornson, director
• Gord Cameron, Corporate Secretary

Jeff Swainson, President & CEO of SSC, stated “The closing of the RTO marks a significant milestone for SSC. We sincerely thank our shareholders and team for their support and commitment, which has ultimately allowed us to achieve this milestone during a time when the cannabis industry has faced significant headwinds. Despite these headwinds, over the past year and a half SSC has built an incredible team, developed a portfolio of fantastic cannabis products, launched two successful brands, Astrolab and Frootyhooty, increased revenue by 900%, achieved net income profitability, and reduced our debt from $9.1 million to zero. As we embark on our journey as a public company, we look to leverage our team, clean balance sheet, revenue growth story, and net income profitability to capitalize on the significant opportunities for organic and inorganic growth that have resulted from these headwinds.”

See Figure 1 and figure 2 for SSC’s brand logos for Astrolab and Frootyhooty.

Prior to closing of the RTO, SSC PrivateCo, Subco and the Company entered into an amended and restated amalgamation agreement (the “A&R Amalgamation Agreement“), which amended and restated the amalgamation agreement dated August 6, 2021, as amended, the details of which are available in the Filing Statement.

The full details of the RTO are set forth in the Filing Statement and the A&R Amalgamation Agreement, each of which are or will be available on SSC’s SEDAR+ profile at www.sedarplus.ca.

Equity Incentive Plan

In connection with closing the RTO, SSC adopted an equity incentive plan (the “Plan“), the details of which are available in the Filing Statement. The Plan allows SSC to grant equity based compensation awards in the form of stock options, restricted share units, deferred share units and performance share units. The Plan is a rolling 10% plan in respect of stock options and a fixed plan in respect of all performance-based awards. There are 48,475,188 Common Shares outstanding immediately following closing of the RTO, therefore up to 4,847,518 Common Shares may be issued upon exercise of stock options issued under the Plan. Up to 4,071,437 Common Shares may be issued upon exercise or settlement of all other awards under the Plan. The aggregate number of Common Shares issuable under the Plan and all other security-based compensation arrangements shall not exceed 10% of the total issued/outstanding shares, in accordance with TSXV Policies. As of the date hereof, SSC has 4,805,000 stock options and no other awards outstanding under the Plan. Amendments to the Plan must be approved by SSC’s shareholders, except for certain changes which are set out in the Plan and in accordance with the policies of the TSXV.

Early Warning Disclosure

Upon the completion of the RTO, Jeff Swainson, President, Chief Executive Officer and Director of SSC, holds, directly or indirectly, or exercises control or direction over an aggregate of 7,378,529 Common Shares, stock options to acquire 450,000 Common Shares and warrants exercisable for the purchase of 1,195,195 Common Shares, representing 15.2% of the issued and outstanding Common Shares on a non-diluted basis, and 18.0% on a partially-diluted basis (assuming the exercise of Mr. Swainson’s convertible securities). Prior to the completion of the RTO, Mr. Swainson did not beneficially own, or exercise control or direction over, any securities of the Company. Mr. Swainson acquired these securities for investment purposes and may, from time to time, acquire additional securities of SSC or dispose of such securities as he may deem appropriate. For the purposes of National Instrument 62-103 – The Early Warning System and Related Take-Over Bid and Insider Reporting Issues  (“NI 62-103“) early warning reporting, the address of Mr. Swainson is 273209 Range Road 20, Rocky View County, Alberta T4B 4P2.

Upon the completion of the RTO, William Macdonald, Director of SSC, holds, directly or indirectly, or exercises control or direction over an aggregate of 5,458,724 Common Shares, stock options to acquire 450,000 Common Shares and warrants exercisable for the purchase of 2,173,725 Common Shares, representing 11.3% of the issued and outstanding Common Shares on a non- diluted basis, and 15.8% on a partially-diluted basis (assuming the exercise of Mr. Macdonald’s convertible securities). Prior to the completion of the RTO, Mr. Macdonald did not beneficially own, or exercise control or direction over, any securities of the Company. Mr. Macdonald acquired these securities for investment purposes and may, from time to time, acquire additional securities of SSC or dispose of such securities as he may deem appropriate. For the purposes of NI 62-103 early warning reporting, the address of Mr. Macdonald is 273209 Range Road 20, Rocky View County, Alberta T4B 4P2.

About Simply Solventless Concentrates Ltd.

SSC is a public company incorporated under the Business Corporations Act (Alberta). SSC’s mission is to provide pure, potent, terpene-rich cannabis products to discerning cannabis consumers. For more information regarding SSC, please see www.simplysolventless.ca.

Notice on Forward Looking Information

This press release contains forward-looking statements and forward-looking information (collectively, “forward-looking statements“) within the meaning of applicable securities laws. Any statements that are contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as “may”, “should”, “anticipate”, “will”, “estimates”, “believes”, “intends” “expects” and similar expressions which are intended to identify forward-looking statements. More particularly and without limitation, this press release contains forward looking statements concerning the resumption of trading of the Common Shares on the TSXV and SSC capitalizing on opportunities for organic and inorganic growth in the cannabis industry. SSC cautions that all forward-looking statements are inherently uncertain, and that actual performance may be affected by a number of material factors, assumptions and expectations, many of which are beyond the control of SSC, including expectations and assumptions concerning SSC, as well as other risks and uncertainties, including those described in SSC’s filings available on SEDAR+ at www.sedarplus.ca. The reader is cautioned that assumptions used in the preparation of any forward-looking statements may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted as a result of numerous known and unknown risks, uncertainties and other factors, many of which are beyond the control and SSC. The reader is cautioned not to place undue reliance on any forward-looking statements. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement.

The forward-looking statements contained in this press release are made as of the date of this press release, and SSC does not undertake any obligation to update publicly or to revise any of the included forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by securities law.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities in any jurisdiction.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

• Completed a Drug Master File (“DMF”) process for CBD Active Pharmaceutical Ingredient (“API”) for the US Federal Drug Administration (“FDA”).
• Use of Canadian Drug Establishment Licence (“DEL”) to register API with the FDA for commercial opportunities in pharmaceutical development, novel drugs and generic drugs.
• The cannabis-based drug opportunity is predicted to be over USD$25 billion by 2025⁽ⁱ⁾.
• This is the only US FDA for CBD by a Canadian company and the second natural CBD DMF at commercial scale in all of North America⁽ⁱⁱ⁾.

TORONTO, Feb. 23, 2022 /PRNewswire/ – MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm” or the “Company”) a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce it has completed a US FDA DMF for pure natural CBD API. The DMF will enable MediPharm to supply approved API to pharmaceutical companies currently conducting late-stage research. The cannabis-based drug opportunity is predicted to be over USD$25 billion by 2025, and there are over 20 strong novel cannabinoid-based drugs currently in the late-stage research process. These projects will all require pharmaceutical approved API if commercialized. MediPharm has already shipped good manufacturing practice (“GMP”) CBD for development purposes to multiple established pharmaceutical companies.

Management Commentary

Bryan Howcroft, CEO, MediPharm, commented, “The filing of a US DMF further advances MediPharm toward its ultimate objective of becoming a dominant supplier of API to pharmaceutical companies. This is a high value, high margin opportunity, and with the only purpose-built facility in North America to receive a domestic GMP license specifically for the extraction of natural cannabinoids, MediPharm is positioned to capture share in this growing market. In the short to medium term, the DMF unlocks new sales channels and will enable us to further leverage the investments made to date on our high-quality pharmaceutical manufacturing platform. Over the longer-term, it ensures the Company is positioned as the go-to cannabinoid partner for pharmaceutical companies around the world.”

Additional Information

DMFs are regulatory submissions filed with the FDA containing confidential, detailed information about manufacturing, processes, packaging, and stability of APIs to be used in medicinal products for human use. Once the DMF filing is accepted by the FDA, pharmaceutical companies can reference the DMF when making a regulatory submission.

There are many large commercial opportunities for an API in new drug applications (“NDAs”) and abbreviated new drug applications (“ANDAs”). NDAs and ANDAs can be divided into the following four categories:

1. A standalone NDA for new novel drugs.
2. A 505(b)(2) application is a NDA where at least some of the information required for approval comes from studies not conducted by or for the applicant.
3. An ANDA for a previous approved drug creating a new generic drug.
4. A petitioned ANDA is a type of ANDA for a drug product that differs from the novel drug in dosage form, route of administration, strength, or active ingredient.

About MediPharm Labs

Founded in 2015, MediPharm specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, API and advanced derivative products utilizing a Good Manufacturing Practices certified facility with ISO standard-built clean rooms. MediPharm has invested in an expert, research driven team, state-of-the-art technology, downstream purification methodologies and purpose-built facilities with five primary extraction lines for delivery of pure, trusted and precision-dosed cannabis products for its customers. Through its wholesale and white label platforms, MediPharm formulates, develops (including through sensory testing), processes, packages and distributes cannabis extracts and advanced cannabinoid-based products to domestic and international markets.

In 2021, MediPharm received a DEL from Health Canada, becoming the only company in North America to hold a domestic GMP License for the extraction of natural cannabinoids. The Company carries out its operations in compliance with all applicable laws in the countries in which it operates.

Cautionary Note Regarding Forward-Looking Information:

This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements relate to, among other things, statements regarding: acceptance of the DMF by the FDA and timing thereof; registering API with the FDA for commercial opportunities in pharmaceutical development, novel drugs and generic drugs; predictions regarding the cannabis-based drug opportunity; supplying approved API to pharmaceutical companies currently conducting late-stage research; becoming a dominant supplier of API to pharmaceutical companies; unlocking new sales channels; enabling the Company to further leverage the investments made to date on its high-quality pharmaceutical manufacturing platform; and positioning the Company as the go-to cannabinoid partner for pharmaceutical companies around the world. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and social uncertainties; the inability of MediPharm to obtain adequate financing; the delay or failure to receive regulatory approvals; and other factors discussed in MediPharm’s filings, available on the SEDAR website at www.sedar.com. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. Except as required by law, MediPharm assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change.

SOURCE MediPharm Labs Corp.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

ROCK CREEK, BC, April 22, 2021 /CNW/ – SpeakEasy Cannabis Club Ltd. (CSE: EASY) (Frankfurt: 39H) (the “Company” or “SpeakEasy“) a holder of a federal licence to cultivate, process and sell cannabis under the Cannabis Act, is pleased to announce that it has completed its product menu for two of its concentrate brands scheduled for release over the next two quarters.  In addition, further to its press releases of January 21, 2021 and April 9, 2021, the Company has completed the transactions contemplated by a convertible loan agreement (the “Loan Agreement“) among the Company, 10161233 Canada Limited, 1287866 B.C. Ltd. (the “Lender“) and Bhayana Ventures Ltd. (the “Administrative Agent“) dated April 9, 2021, for aggregate gross proceeds of CDN$3,000,000 (the “Loan“).

Product Development

SpeakEasy has created a complete line of products formulated from its fresh frozen and dried cannabis material that will be launched under two separate brands scheduled to be introduced over the next two quarters. We have studied the markets in Canada and in the US, noting that certain market trends are favorable and therefore we have created products based on both existing products in high demand and others that are not yet in this country. Formulating these products has been a multi-year project involving genetics, outdoor cultivation, acquisition and development of intellectual property in addition to the acquisition of equipment that can produce the desired products. The advantage of having low-cost input material gives SpeakEasy the ability to enter markets focusing on the lowest priced competitor as an entry price point.

The Importance of Brands

Management believes that branding makes the cannabis industry more legitimate in the eyes of the consumer which, in turn, drives brand recognition. As the cannabis industry grows, and new differentiating entrants come into the market, the sure-way to survive is by building a unique brand experience within a particular niche. We feel SpeakEasy’s history and overall philosophy gives us a unique connection to consumers by telling a story through our brands which will be an important part of creating customer loyalty and brand recognition.

Founder Marc Geen, Canopy Growth’s recent acquisition of Supreme Cannabis for $435 million is a clear indication in the value of brand equity. From day one, we have invested a huge amount of time in building brands for our future. We believe we’re in a unique position to create quality products at low-cost while being immersed in our culture. Authenticity is the biggest factor to building real brands that customers want to engage with. It’s not a brand until your audience is willing to wear your logo because of the values you represent. It’s exciting times over here.”

Extract Product Portfolio

SpeakEasy has created and tested a menu of over 25 unique products that are now ready for launch. Once we receive our amended sales licence, expected within the next 45 days, we will be able to introduce brands and products to the market. We have established production, processing and packaging methods and anticipate entering into contracts with multiple provinces once we are granted our amended sales licence. Many of the products that we are developing are not yet available to the Canadian market however once they are launched, we expect they will be priced aggressively with a view to capturing additional market share.

Convertible Loan Financing of CDN$3.0 Million

The Company has completed the transactions Loan Agreement for aggregate gross proceeds of CDN$3,000,000.

In accordance with the terms and conditions of the Loan Agreement, the Company has issued the Administrative Agent an aggregate of 288,462 common shares in the capital of the Company (the “Common Shares“), at a deemed price of $0.52 per share, in satisfaction of the payment of a finder’s fee.  In addition, the Company has granted the Administrative Agent an aggregate of 5,769,231 Common Share purchase warrants (the “Warrants“). Each Warrant entitles the holder to purchase a Common Share at a purchase price of $0.70 per Common Share, subject to adjustment, until April 21, 2024.

The principal amount of the Loan and any accrued but unpaid interest thereon will be convertible into Common Shares at the option of the Administrative Agent (on behalf of the Lender) at a price of $0.52 per Common Share, subject to adjustment, in accordance with the terms and conditions set forth in the Loan Agreement.

Option Grant

The Company also announces the grant of an incentive stock option to purchase up to 200,000 common shares (the “Options“) to a consultant of the Company, such Option to be granted in accordance with applicable laws and the policies of the Canadian Securities Exchange.

Shares for Debt

The Company also announces that it intends to issue an aggregate of 18,657 Common Shares in settlement of bona fide debt owing to an arm’s length creditor in the amount of $12,500.  The Common Shares will be issued at a deemed price of $0.67 per share.

Proposed Board Member

In connection with the Company’s annual general meeting of shareholders scheduled to occur on April 28, 2021, management of the Company understands that a nomination from the floor will be made for the election of Ryan Kennedy as an additional independent director of the Company. The election of Mr. Kennedy would be contingent upon his receipt of security clearance by Health Canada.  The nomination of Mr. Kennedy is supported by management and the Company recommends that shareholders vote in favour of the contingent election of Mr. Kennedy as a director of the Company.

Mr. Kennedy resides in Penticton, British Columbia, where he has been the President of WestRep Solutions, a manufacturer’s representative agency since April 2000.  Mr. Kennedy currently holds, or exercises control over, 716,425 Common Shares.

Mr. Kennedy is a well-respected entrepreneur with a depth of experience in strategic planning and management.  He brings more than 28 years’ experience in creating start ups, strategic planning, selling and marketing products, and building business relationships.

Malcolm Davidson, CEO states, “We are looking forward to working with Ryan and harvesting some of the valuable knowledge and guidance he brings to the table as we implement our initiatives to further our corporate strategies and goals and build on our strong governance.”

About SpeakEasy Cannabis Club Ltd.

SpeakEasy Cannabis Club Ltd. holds a cultivation, processing and sales licence issued by Health Canada under the Cannabis Act. SpeakEasy owns 290 acres of land in Rock Creek, British Columbia, and leverages five generations of farming experience in B.C. as well as its favourable location to grow and process high-quality cannabis products at low cost. SpeakEasy cultivates small batch, high quality craft cannabis at scale in a portion of its 63,200 square foot indoor cannabis complex and has completed its harvest of its 60-acre outdoor field. Total yearly production of cannabis flower and biomass is projected to be in excess of 70,000 kilograms per year once in full production.

On behalf of the Board of the Directors

Forward Looking Statement

This news release contains statements that constitute “forward-looking statements.” Such forward looking statements involve known and unknown risks, uncertainties and other factors that may cause SpeakEasy’s actual results, performance or achievements, or developments in the industry to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects,” “plans,” “anticipates,” “believes,” “intends,” “estimates,” “projects,” “potential” and similar expressions, or that events or conditions “will,” “would,” “may,” “could” or “should” occur.

Forward-looking statements in this document include statements concerning SpeakEasy’s expectations concerning its brands; the availability of its products, including the pricing sales and the timing thereof; its expectations that concerning receipt of an amendment to its licence and the timing thereof; its expectations regarding the nomination and election of Ryan Kennedy, and its intent to produce and sell high quality craft cannabis, and all other statements that are not statements of historical fact.

Although SpeakEasy believes the forward-looking information contained in this news release is reasonable based on information available on the date hereof, by their nature forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.  By their nature, these statements involve a variety of assumptions, known and unknown risks and uncertainties and other factors, which may cause actual results, levels of activity and achievements to differ materially from those expressed or implied by such statements.

Examples of such assumptions, risks and uncertainties include, without limitation, assumptions, risks and uncertainties associated with general economic conditions; COVID-19, adverse industry events; future legislative and regulatory developments involving cannabis; the Company’s ability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favorable terms; the cannabis and hemp industries and markets in Canada and generally; the demand for CBD distillate, cannabis and cannabis related products, the ability of SpeakEasy to implement its business strategies; competition; the ability of SpeakEasy to obtain and retain all applicable licences under the Cannabis Act and other assumptions, risks and uncertainties.

THE FORWARD-LOOKING INFORMATION CONTAINED IN THIS NEWS RELEASE REPRESENTS THE EXPECTATIONS OF THE COMPANY AS OF THE DATE OF THIS NEWS RELEASE AND, ACCORDINGLY, IS SUBJECT TO CHANGE AFTER SUCH DATE. READERS SHOULD NOT PLACE UNDUE IMPORTANCE ON FORWARD-LOOKING INFORMATION AND SHOULD NOT RELY UPON THIS INFORMATION AS OF ANY OTHER DATE. WHILE THE COMPANY MAY ELECT TO, IT DOES NOT UNDERTAKE TO UPDATE THIS INFORMATION AT ANY PARTICULAR TIME EXCEPT AS REQUIRED IN ACCORDANCE WITH APPLICABLE LAWS.

The Canadian Securities Exchange nor its Regulation Services accepts responsibility for the adequacy or accuracy of this release.

SOURCE Speakeasy Cannabis Club Ltd.

For further information: Malcolm Davidson, CEO, [email protected], 1-604-218-9797

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

RED DEER, AB, April 6, 2021 /CNW/ – Stigma Grow (“Stigma” or the “Company”) and its parent company, CanadaBis Capital Inc. (TSXV: CANB), are thrilled to announce they have entered into a third-party production agreement (the “Agreement”) with Sundial Growers Inc. (NASDAQ: SNDL) (“Sundial” or the “Company”), a Health Canada licensed cannabis producer recognized for its ‘small-batch-at-scale’ individualized ‘room’ approach, to produce a variety of Sundial’s hydrocarbon (BHO) concentrates.

Among other opportunities within the concentrates market, the new collaboration between the two Alberta-based companies will enable capitalization on the fast-emerging live-resin vape market.

Under the terms of the Agreement, Sundial will provide its input for both fresh-frozen and cured formats to Stigma to produce a variety of live-resin and cured cannabis concentrates.

Sundial expects to launch the products across Canada under the Top Leaf brand in Q3 2021.

“As one of the first-to-market producers of true live-resin, high-terpene, full-spectrum vape cartridges in Alberta we reviewed many partnership requests from some of legal cannabis’ most recognizable brands, but none provided the brand and business fit demonstrated by Sundial,” said Travis McIntyre, CEO of Stigma. “We look forward to working with this well-established Alberta brand long into the future and recognize the value that comes to those who partner strategically with like-minded visionaries.”

“As part of our continued focus within the premium inhalable segment, we are pleased to enter into a concentrates partnership with Stigma,” added Andrew Stordeur, President and Chief Operating Officer of Sundial.  “We believe this collaboration will provide our consumers with an excellent addition to our portfolio of cannabis products.”

In addition to this partnership announcement, the first two months of 2021 has seen the Company’s existing and new products accepted into Ontario, British Columbia, Manitoba and Saskatchewan, as education surrounding the quality and experience offered by live-resin concentrates makes its way across the country to millions of recreational and medicinal consumers typically looking for something new and improved.

About CanadaBis Capital Inc. & Stigma Grow

CanadaBis Capital Inc. (TSXV:CANB) is a vertically integrated Canadian cannabis company focused on achieving large-scale growth in the global cannabis market – with specific attention paid to supplying the fast-emerging concentrates category through their Stigma Grow cultivation and extraction facility.

Acting as the cornerstone for everything they offer, Stigma Grow continuously strives to address the market demands and lingering stigmas within the legal cannabis industry head-on, with products designed to disturb the status quo and dramatically shift the conversation surrounding Canada’s legal cannabis industry.

About Sundial Growers Inc. 

Sundial is a public company with Common Shares traded on Nasdaq under the symbol “SNDL”.

Sundial is a licensed producer that crafts cannabis using state-of-the-art indoor facilities. Our ‘craft-at-scale’ modular growing approach, award-winning genetics and experienced growers set us apart.

Our Canadian operations cultivate small-batch cannabis using an individualized “room” approach, with 448,000 square feet of total available space.

Sundial’s brand portfolio includes Top Leaf, Sundial Cannabis, Palmetto and Grasslands. Our consumer-packaged goods experience enables us to not just grow quality cannabis, but also to create exceptional consumer and customer experiences.

We are proudly Albertan, headquartered in Calgary, AB, with operations in Olds, AB, and Rocky View County, AB.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION:

This news release includes certain “forward-looking statements” under applicable Canadian securities legislation. Forward-looking statements include but are not limited to statements with respect to our business and operations; timing of the Sundial products coming to market; the demand and market for live-resin vape cartridges, and our general business plans. Forward-looking statements are necessarily based upon a number of assumptions including: the ability of the Company’s products to compete with the pricing and product availability on the black-market; the market demand for the Company’s products; and assumptions concerning the Company’s competitive advantages. These assumptions, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: compliance with extensive government regulation, the general business, economic, competitive, political and social uncertainties; ability to sustain or create a demand for a product; requirement for further capital; delay or failure to receive board, shareholder or regulatory approvals; the results of operations and such other matters as set out in the Company’s continuous disclosure on SEDAR at www.sedar.com. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.

Accordingly, readers should not place undue reliance on forward-looking statements. Investors are cautioned that forward-looking information is not based on historical facts but instead reflects management’s expectations, estimates or projections concerning future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although we believe that the expectations reflected in such forward-looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have a material adverse effect on our future results, performance or achievements.

Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The Company does not intend, and does not assume any obligation, to update this forward-looking information except as otherwise required by applicable law.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE CanadaBis Capital Inc.

For further information: For more information on CanadaBis Capital or Stigma Grow visit: www.canadabis.com, www.stigmagrow.ca, or contact: Investor Relations [email protected] 1-888-STIGMA1

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

The legalization of cannabis in Canada on October 17, 2018 was seen as a progressive and forward-thinking development.It put Canada at the forefront of this exciting new industry, as the only country other than Uruguay to legalize cannabis on a federal level. However as dynamic as this legislation was, it was limited in terms of what was initially included. Although flower was covered under these new laws, they excluded a huge part of the industry; edibles and concentrates.

A report by Arcview Market Research estimated that cannabis-based food and drink reached an estimated $1 billion in 2017 in North America. The same report estimates the edibles market could reach an astounding $4.1 billion in the US and Canada by 2022.

Canadian Edibles Market

The Canadian market is preparing to capitalize on this trend. In late December, Health Canada released draft regulations, which dictate that edible cannabis products should be fully legalized by October 17 of this year. A recent report from Deloitte entitled ‘Nurturing new growth: Canada gets ready for Cannabis 2.0’ estimates the annual market for alternative cannabis products to be $2.7 billion, with edibles contributing to over half of that.

Click here to see the company’s investor presentation

With this incredible business opportunity, producers and distributors are looking at ways to capitalize on this vast new sector of the market. One company which looks to be well-positioned in this category is Indiva Limited(TSXV:NDVA) (US:NDVAF).

As a Licensed Producer of medical grade cannabis, Indiva is perfectly positioned for Cannabis 2.0. It has a growing roster of brands which already produce and distribute a wide variety of cannabis products to users across Canada. As an established company, Indiva plans to use its Canadian operations as a platform to launch into the edibles market, once the surrounding legislation is finalized.

Facilities and Distribution

Indiva has a 100%-owned, 40,000 square foot indoor production facility in London, Ontario. Its facility is world class, with quality assurance and control. A clean product is ensured by its climate controlled system, as well as pest and pathogen control. Its GMP-compliant, aeroponic grow systems are environmentally friendly and highly advanced. Already producing medical grade THC, CBD and hybrid strains, Indiva is positioned to use this facility to produce equally high-grade edible cannabis products.

In early June Indiva received an amended license from Health Canada for three additional grow rooms and three additional processing rooms, bringing the company’s annual cultivation capacity to approximately 1,000kg. The increased flower capacity will serve as raw material for Indiva’s 70 tonne extraction facility which is scheduled for completion in Q3 of 2019. Indiva’s extraction system will produce some 4 million grams of distillate annually at full capacity with the potential to be more profitable than flower at current market conditions. The three newly licensed rooms will be immediately populated with plants, using advanced aeroponic grow technology, with the first harvest expected in less than 10 weeks.

Click here to see the company’s investor presentation

Indiva has a supply agreement in place with the Ontario Cannabis Store (OCS) and has been delivering on the order since February and is preparing to deliver gel capsules.The agreement with the OCS has resulted in Q1 net revenue gains for Indiva. The company is executing on plans to grow its facilities and product offerings and awaits approval and licensing from Health Canada. Going forward, the company aims to add further distribution agreements with retailers in other provinces in 2019, using its active sales team already located across the country.

In the longer-term, Indiva plans to use its Canadian operations as a blueprint to launch globally into new markets, as cannabis laws around the world continue to come into play.

Indiva already has agreements with US based companies to distribute internationally, and it has issued a Letter of Intent to acquire a cultivation license in Denmark, where a four year pilot program which began in January 2018 allows the sale of medical cannabis. This would give Indiva an early advantage in the European market, which should become particularly lucrative as laws liberalize across the continent.

Impressive Product Line

Among its brands, Indiva has aligned itself with high-quality and experienced edible companies, namely Ruby and Bhang. Both companies are powered by Indiva, and will use the company’s cannabis oil extractions as the basis for edible products.

Ruby is the world’s first edible brand made with organic and all-natural ingredients. The product line will consist of infused sugar and salt crystals, which allows users to easily incorporate them into food and drink for the ultimate in personalized edible cannabis consumption. The line also offers fruit-based chews, pancake and drink mixes, candies and prebiotic supplements. The line will be infused with Indiva’s THC, CBD or a hybrid combination of both, offering a wide selection for those who wish to ingest cannabis, not inhale it.

Bhang Chocolate is one of the most recognised cannabis brand houses on the planet. Drawing from its diverse team, Bhang brings together over a decade of experience in the cannabis industry to create its award-winning product line. With reliable dosing and a cannabis-free taste, Bhang’s products are the ultimate in premium edibles. In addition to its range of cannabis-infused chocolates, Bhang also offers vapes, gums and mouth sprays.

Experienced Leadership

Indiva is led by CEO, Director and Co-Founder Niel Marotta. Niel managed a portfolio of over $1 billion as a fund manager at a notable US firm. He was also Vice President of a TSX listed natural resource focused company, and subsequently worked as an investment banker. As a graduate of McGill University’s commerce programme, Niel is the perfect leader to guide Indiva into this exciting new branch of the cannabis industry.

Click here to see the company’s investor presentation

Between its state of the art facility, calculated distribution network and expanding product offering, Indiva has set its sights high as Canada’s legal market enters the next phase of its development, the cannabis 2.0 revolution. With analysts predicting this to be a multi-billion dollar segment of the marijuana industry, Indiva has taken intelligent and bold steps to lay the groundwork for its success as edibles are legalized in Canada.

Disclaimer

The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

About Joy Crosby